Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients

References

• RenRMechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemiaNat Rev Cancer20055317218315719031
   PubMed Web of Science ®Google Scholar
• IcHCurrent management of chronic myeloid leukemia with tyrosine kinase inhibitorsTurkish J Hematol201330247255
   PubMed Web of Science ®Google Scholar
• FerdinandRMitchellSABatsonSTumurITreatments for chronic myeloid leukemia: a qualitative systematic reviewJ Blood Med20123517622915985
   PubMedGoogle Scholar
• HochhausAO’BrienSGGuilhotFIRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia20092361054106119282833
   PubMed Web of Science ®Google Scholar
• KantarjianHMGilesFGattermannNNilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood2007110103540354617715389
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFWunderleLNilotinib in imatinib-resistant cml and Philadelphia chromosome-positive ALLN Engl J Med2006354242542255116775235
   PubMed Web of Science ®Google Scholar
• RostiGPalandriFCastagnettiFNilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaBlood2009114244933493819822896
   PubMed Web of Science ®Google Scholar
• KantarjianHMHochhausASaglioGNilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialLancet Oncol201112984185121856226
   PubMed Web of Science ®Google Scholar
• CortesJEJonesDO’BrienSNilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phaseJ Clin Oncol201028339239720008621
   PubMed Web of Science ®Google Scholar
• Cancer Institute NCommon terminology criteria for adverse events (CTCAE) Version 4.02009 Available from: http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdfAccessed June14, 2010
   Google Scholar
• BaccaraniMDeiningerMWRostiGEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood2013122687288423803709
   PubMed Web of Science ®Google Scholar
• JainPKantarjianHAlattarMLAnalysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities – analysis of 5 prospective clinical trialsLancet Haematol201523e118e12826687797
   PubMed Web of Science ®Google Scholar
• HughesTPCoutrePDJootarSLRAENESTnd 5-year follow-up: continued benefit of frontline nilotinib (NIL)compared with imatinib (IM) in patients (PTS) with chronic myeloid leukemia in chronic phase (CML-CP)Haematologica201499s1236237
   Google Scholar
• LarsonRAKimD-WIssaragrilsilSEfficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f/u) of ENESTndBlood2014124214541
   Web of Science ®Google Scholar
• CortesJEJonesDO’BrienSResults of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemiaJ Clin Oncol201028339840420008620
   PubMed Web of Science ®Google Scholar
• AzizZIqbalJAkramMSaeedSTreatment of chronic myeloid leukemia in the imatinib eraCancer200710961138114517315159
   PubMed Web of Science ®Google Scholar
• SaußeleSRichterJHochhausAMahonFXThe concept of treatment-free remission in chronic myeloid leukemiaLeukemia20163081638164727133824
   PubMed Web of Science ®Google Scholar
• NicoliniFENoëlM-PEscoffreMPreliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinibBlood201312221654
   Google Scholar
• TakahashiNKyoTMaedaYDiscontinuation of imatinib in Japanese patients with chronic myeloid leukemiaHaematologica201297690390622180435
   PubMed Web of Science ®Google Scholar
• OyekunleAAOshoPOAnekeJCSalawuLDurosinmiMAThe predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib eraJ Hematol Malig2012222532
   Google Scholar
• YahngSAJangEJChoiSYLeeSEKimSHKimDWPrognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean populationInt J Hematol2014100213214024879034
   PubMed Web of Science ®Google Scholar
• HasfordJBaccaraniMHoffmannVPredicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreBlood2011118368669221536864
   PubMed Web of Science ®Google Scholar
• YamamotoEFujisawaSHagiharaMEuropean treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patientsCancer Sci2014105110510924450386
   PubMed Web of Science ®Google Scholar
• KuntegowdanahalliLCKanakasettyGBThankyAHPrognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in Southern IndiaEcancermedicalscience20161067927899952
   PubMedGoogle Scholar
• BansalSPrabhashKParikhPChronic myeloid leukemia data from IndiaIndian J Med Paediatr Oncol201334315415824516297
   PubMedGoogle Scholar
• UsmanMSyedNNKakepotoGNAdilSNKhurshidMChronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic responseJ Assoc Physicians India20075510310717571738
   PubMedGoogle Scholar
• SoveriniSGnaniAColarossiSPhiladelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsBlood2009114102168217119589924
   PubMed Web of Science ®Google Scholar
• BranfordSMeloJVHughesTPSelecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Blood2009114275426543519880502
   PubMed Web of Science ®Google Scholar
• ReaDManagement of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemiaAnn Hematol201594Suppl 2149158
   Google Scholar
• RostiGCastagnettiFGugliottaGPalandriFBaccaraniMPhysician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CMLCancer Treat Rev201238324124821840128
   PubMed Web of Science ®Google Scholar
• SteegmannJLBaccaraniMBrecciaMEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaLeukemia20163081648167127121688
   PubMed Web of Science ®Google Scholar